Antiviral From Advanced Viral Research Corp. Inhibits Production of a Key Cervical Cancer-Causing Protein of the Human Papilloma Virus.YONKERS, N.Y.--(BUSINESS WIRE)--Oct. 26, 1999-- Advanced Viral Research Corp. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ADVR ADVR Association of Directors of Volunteer Resources (Canada) ) Tuesday announced that its anti-viral peptide nucleic acid type drug, Substance R, has been found to inhibit the production of a key cancer-causing protein of the human papilloma virus human papilloma virus n. Abbr. HPV A DNA virus of the genus Papillomavirus, certain types of which cause cutaneous and genital warts in humans, including condyloma acuminatum. . Human papilloma virus (HPV HPV human papillomavirus. HPV abbr. human papilloma virus Human papilloma virus (HPV) ) is a world-wide sexually transmitted infection causing genital warts. Several subtypes of HPV, including subtypes 16 and 18, are associated with the development of cervical cancer in infected women. The expression of the E7 protein of these tumor-causing HPV subtypes is important in the development of cervical cancer. Using a human cervical cancer cell line that carries the DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. of HPV subtype 18, scientists at Advanced Viral Research Corp. showed that Substance R inhibited the expression of the E7 protein. Commenting on this research, Dr. Shalom Z. Hirschman, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Advanced Viral Research Corp., stated: "This exciting discovery by our scientists - that our antiviral peptide-nucleic acid type drug, Substance R, interferes with the expression of the E7 gene - offers a novel approach to the development of therapeutic agents for the treatment of HPV infection and cervical cancer. This new finding may account, in part, for the beneficial effects of Substance R in the treatment of HPV-infected individuals observed in preliminary clinical trials. Furthermore, this result suggests that Substance R may prove useful in both the prevention and treatment of cervical cancer caused by HPV infection." Advanced Viral Research Corp. is a biotechnology-pharmaceutical firm primarily engaged in developing peptide-nucleic acid therapies. Its flagship drug, Substance R (Reticulose(tm)), is an immunomodulator that exerts beneficial therapeutic effects against viral diseases, such as AIDS. For further information, contact Alan Gallantar at 914/376-7383. NOTE: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. , product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Substance R (Reticulose(tm)) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion